Analysts at Stifel are bullish about Illumina, Inc.’s (NASDAQ:ILMN) prospects despite the stock capitulating 36% year to date ...

On May 24, analysts at Stifel reaffirmed their Buy rating and price target of $48 for Bicara Therapeutics Inc. (NASDAQ:BCAX).

Citing what they call the S&P 500 price-to-earnings mania, Stifel is once again recommending that what it calls “defensive ...

Stifel Financial (SF) reported selected operating results for April 30 in an effort to provide timely information to ...

The broker-dealer alleged that a FINRA arbitration panelist who helped hand down the landmark penalty should have recused ...

In addition to Stifel Nicolaus, Cytokinetics also received a Buy from H.C. Wainwright’s Joseph Pantginis in a report issued on May 19. However, on May 13, Bank of America Securities maintained a Hold ...

The St. Louis-based financial services giant has inked what officials called an "unprecedented" extension of its sponsorship ...

Stifel Financial Corp. reported key operating metrics for April 30, 2025, highlighting a 7% increase in total client assets and an 11% rise in fee-based assets compared to the previous year ...